The PMAD Detection Gap in OB Practice: How Many of Your Patients Are Being Missed

In a practice seeing 200 postpartum patients per year, 30 to 40 of them will develop a clinically significant PMAD: postpartum depression, postpartum anxiety, birth trauma, OCD with postpartum onset, or some combination. In practices with no systematic screening protocol, the number identified in a given year is typically closer to 4 to 10.

The rest go home without a referral. Most do not know that what they are experiencing is a recognized medical condition. Most will not follow up with their OB. Many will struggle for months before either seeking help independently, or not seeking it at all.

This is not a failure of clinical intent. It is a structural problem, and it has a structural solution.

---

The Detection Gap by the Numbers

The gap between PMAD prevalence and PMAD detection in routine OB care is large and well-documented.

A 2016 systematic review published in JAMA found that approximately 10-15% of postpartum women meet criteria for major depressive disorder, with anxiety disorders affecting an additional 10-20%. The combined PMAD burden in a typical postpartum population is approximately 20-25% when depression and anxiety-spectrum conditions are both counted.

Detection rates in unscreened practices, based on retrospective chart review studies, cluster around 2-5%. In practices that implement systematic screening with the EPDS at defined visit intervals, detection rates increase to 15-25%. The difference is not explained by the patient population, the severity of presentations, or the clinical skill of individual providers. It is explained by whether screening is built into the care delivery system.

USPSTF issued a Grade B recommendation for depression screening in all adults, including pregnant and postpartum women, in 2016. The same body issued a Grade B recommendation for anxiety screening in adults in 2023. Both recommendations apply across the perinatal period. A practice relying on patient self-disclosure to identify PMADs is not meeting either guideline.

---

Why Patients Do Not Self-Report

When asked directly, most patients with untreated PMADs offer recognizable explanations for why they did not tell their provider:

"I didn't think it was bad enough." The threshold problem is pervasive. Patients compare their experience to a worst-case template for postpartum depression (crying all day, unable to function) and conclude they fall short. Anxiety-predominant presentations (constant worry, inability to sleep, racing thoughts) are particularly likely to be framed as "stress" rather than as a medical issue warranting clinical attention.

"I was afraid they would think I was a bad mother." Fear of judgment, and more specifically fear of child protective services involvement, is documented as a barrier to disclosure in multiple qualitative studies. Patients with intrusive thoughts (postpartum OCD) are particularly likely to conceal symptoms out of fear that disclosing them will result in the baby being removed.

"I didn't know this was something a doctor could help with." A significant proportion of patients with PMADs have no prior experience with mental health treatment and no framework for understanding their symptoms as medical rather than personal. The cultural infrastructure for understanding postpartum depression is improving but remains insufficient.

"The appointment was about my physical recovery." The six-week OB postpartum visit is brief, covers significant ground, and is framed around physical healing. Patients who are struggling emotionally but physically recovering normally may not experience the appointment as a space for psychological disclosure.

Each of these barriers is predictable. Systematic screening removes the reliance on patients self-identifying that their experience is clinical, finding the language to describe it, and deciding a medical appointment is the right place to raise it. A validated screening instrument does not ask patients to volunteer their struggles; it asks them structured questions and lets the score speak.

---

The Time-Point Problem

The six-week postpartum visit is the most common single screening point. It is not sufficient.

Three distinct timing problems compound the detection gap when screening is limited to the six-week visit:

Late-onset presentations. Postpartum depression does not always peak in the immediate postpartum period. Some presentations develop or intensify between six weeks and six months, as immediate postpartum support (hospital staff, family visitors, partner leave) recedes and the reality of ongoing care without infrastructure becomes apparent. A patient who screens negative at six weeks may develop a clinically significant PMAD at week ten.

Anxiety-predominant presentations. Postpartum anxiety often manifests as hypervigilance that is hard to distinguish from appropriate new-parent concern in a brief clinical encounter. The patient is not obviously distressed: she is alert, organized, attending appointments on time, asking thorough questions. The internal experience of constant threat monitoring, inability to rest, and catastrophic ideation is not visible. A validated anxiety instrument surfaces it; a brief check-in often does not.

The brief visit ceiling effect. A fifteen-minute postpartum visit leaves limited space for a patient to disclose psychological distress, especially if the appointment begins with vital signs, incision or perineal assessment, and contraception discussion. The screening instrument needs to precede the clinical encounter, not be wedged into it.

AAP guidelines recommend screening mothers at the one-, two-, four-, and six-month well-child visits, specifically because pediatric encounters capture a period when OB contact has ceased but postpartum mental health risk is still elevated. Pediatric practices that screen the mother at well-child visits are catching cases that OB practices miss.

---

The Cost of the Gap

Untreated postpartum depression persists an average of seven months. Anxiety disorders without treatment persist longer. Neither resolves reliably without intervention.

The downstream effects extend beyond the individual patient:

Infant development. Maternal depression during infancy is associated with disrupted attachment, impaired cognitive and language development, and behavioral outcomes that persist into school age. The effect is not explained by genetics or socioeconomic factors alone; the quality of early parent-infant interaction, which is directly compromised by maternal depression, is independently associated with developmental outcomes.

Partner health. Postpartum depression in one parent is predictive of elevated depression risk in the other. Studies find that fathers and non-birthing partners of mothers with PPD have a two- to three-fold elevated depression risk. Identifying and treating the postpartum patient protects the family unit.

Subsequent pregnancy. Untreated prior PMAD is among the strongest risk factors for PMAD in a subsequent pregnancy. Patients who receive treatment and establish a referral relationship for perinatal mental health support are better positioned to identify and address recurrence early.

---

What Systematic Screening Changes

Practices that implement systematic PMAD screening with validated tools, defined timing intervals, and a referral protocol see:

• Detection rates that approach PMAD prevalence, rather than a fraction of it
• Earlier identification: patients found at lower severity levels who respond faster to treatment
• Shorter time from symptom onset to treatment initiation
• Reduced downstream referrals for infant feeding difficulties, sleep problems, and relationship issues that were downstream effects of unaddressed maternal mental health

The clinical investment is measurable: the EPDS takes five to ten minutes to complete. The triage decision adds two to three minutes of chart review. The referral conversation, when needed, takes two to three minutes. The total time commitment for a patient who screens positive is under ten minutes per encounter.

For guidance on choosing the right screening instrument and timing windows, see EPDS vs. PHQ-9 vs. GAD-7: Choosing a PMAD Screening Tool for OB and Midwifery Practices.

For the referral decision framework (who to refer, what to say, and how to manage resistance), see When and How to Refer Postpartum Patients for Mental Health Support.

For a step-by-step implementation guide covering staff roles, EHR documentation, and score triage, see How to Build a Postpartum Depression Screening Workflow in Your OB Practice.

---

FAQ

What Percentage of Postpartum Patients Have Undiagnosed PMADs

Estimates vary by study, but practices without systematic screening identify 2-5% of affected patients, while practices using validated tools at defined intervals identify 15-25%. Given that 1 in 5 postpartum people develops a clinically significant PMAD, the unscreened gap represents the majority of affected patients in most practices.

Why Do Patients Not Self-Report PMAD Symptoms to Their OB

Several well-documented barriers prevent self-disclosure: fear of judgment, fear of being perceived as a bad mother, not knowing that symptoms represent a medical condition, minimizing relative to a perceived worst-case, and the brevity of postpartum visits. Studies find that direct screening nearly always outperforms self-disclosure as a detection method.

Does Screening at the 6-Week Visit Catch Most Cases

No. The 6-week visit is the most common single screening point, but it misses late-onset presentations (PPD can develop or peak after 6 weeks), patients whose symptoms intensify as support fades (often 8-12 weeks), and patients who minimize at a brief appointment. Clinical guidelines increasingly support screening at multiple time points through 6 months postpartum.

What Is the Clinical Impact of Untreated Postpartum Depression

Untreated postpartum depression persists an average of 7 months. Beyond maternal wellbeing, the evidence base shows downstream effects on infant development (disrupted attachment, impaired cognitive and language development) and partner mental health (two- to three-fold elevated depression risk). The cost of not identifying and treating PMADs extends across the family unit.

---

Interested in setting up a perinatal mental health referral pathway for your practice? Phoenix Health partners with OB, midwifery, and pediatric practices to create structured referral arrangements. Contact our clinical partnerships team to discuss what that looks like.